Night Pain | Aspirin Relief | Nidus Under 2cm | RFA vs Excision
- Night pain relieved by NSAIDs/aspirin - classic presentation
- Nidus under 2cm - larger is osteoblastoma (same histology)
- CT is gold standard - shows nidus within reactive sclerosis
- RFA first-line treatment - 90%+ success, day case procedure
- Surgical excision if RFA fails or for specific locations
- “Nidus under 2cm differentiates from osteoblastoma
- “Bone scan hot with double-density sign
- “Pain mechanism: prostaglandins from nidus
- “May cause scoliosis in spine (painful type)
Under 2cm equals osteoid osteoma while over 2cm equals osteoblastoma. Same histology, different behaviour. Osteoblastoma is more aggressive and has higher recurrence. This is the key exam distinction.
Classic history is nocturnal pain that wakes patient, relieved by aspirin or NSAIDs within 20-30 minutes. Due to prostaglandin E2 production by the nidus.
X-ray may be normal or show reactive sclerosis. CT is diagnostic and shows the nidus. MRI can be misleading due to extensive oedema. Bone scan shows characteristic uptake.
RFA is first-line in most locations. Surgical excision reserved for RFA failure, spinal canal locations, or surgeon preference. Both achieve over 90% success.
- First Choice
- CT-guided RFA
- Alternative
- Surgical excision (en bloc)
- Special Considerations
- Most common location, excellent RFA access
- First Choice
- RFA with nerve monitoring
- Alternative
- Surgical excision
- Special Considerations
- Risk of thermal injury to neural structures
- First Choice
- Arthroscopic excision
- Alternative
- RFA with chondroprotection
- Special Considerations
- Cartilage damage risk with RFA
- First Choice
- Surgical excision
- Alternative
- RFA
- Special Considerations
- Risk of fracture, limited bone stock
- First Choice
- Surgical excision
- Alternative
- Cryoablation
- Special Considerations
- Thermal damage to physis with RFA
NIDUSNIDUS - Osteoid Osteoma Features
Hook:The NIDUS is what you're looking for on CT - under 2cm with reactive sclerosis
SCLEROSISSCLEROSIS - Imaging Features
Hook:Remember the SCLEROSIS you see is reactive - focus on finding the small nidus
RFARFA - Radiofrequency Ablation Steps
Hook:RFA destroys the nidus that produces the prostaglandins causing pain
Overview and Epidemiology
Definition
Osteoid osteoma is a benign osteoblastic bone tumour characterised by a small nidus (under 2cm) of osteoid tissue surrounded by reactive bone sclerosis. It is histologically identical to osteoblastoma but distinguished by size and clinical behaviour.
Epidemiology
- Accounts for 10-12% of benign bone tumours
- Annual incidence approximately 3 per million population
- More common than osteoblastoma (3:1 ratio)
- Peak age 10-25 years (80% under 30)
- Male predominance 2:1 to 3:1
- All ethnic groups equally affected
- Lower extremity 50-60% (femur and tibia most common)
- Upper extremity 20%
- Spine 10-15%
- Hand and foot 10%
Natural History
Without treatment, osteoid osteomas typically follow a predictable course with persistent symptoms for 3-5 years before spontaneous resolution. Approximately 5-10% resolve within 2 years while most cases take 3-6 years for complete spontaneous regression. Some cases persist beyond 6 years without resolution.
The regression occurs due to maturation of the nidus into inactive sclerotic bone, with gradual cessation of prostaglandin production.
Risk Factors
No clear risk factors have been identified. The tumour is not associated with trauma, infection, or inherited conditions. It represents a true neoplasm rather than a reactive process.
Anatomy and Pathophysiology
Lesion Characteristics
Osteoid osteoma is a benign bone-forming tumour characterised by a small central nidus (under 2cm) surrounded by reactive sclerotic bone. The nidus consists of osteoid tissue in various stages of maturation, surrounded by highly vascularised connective tissue stroma.
Nidus Components:
- Central zone of osteoid and woven bone
- Highly vascularised connective tissue stroma
- Osteoblasts rimming the osteoid trabeculae
- Variable mineralisation (central calcification common)
"Histologically identical to osteoblastoma" is repeated everywhere, but you should be able to describe what the nidus actually looks like and why it can be misread:
- The nidus is composed of haphazardly interconnecting trabeculae of woven bone and osteoid, rimmed by a single layer of plump but cytologically bland osteoblasts, set in a loose, richly vascular fibrous stroma (which carries the unmyelinated nerve fibres that mediate pain).
- It is sharply demarcated from the surrounding dense reactive (sclerotic) host bone - this circumscription, and the absence of permeation/entrapment of pre-existing lamellar bone, is a key feature.
- The biopsy trap: on a small or fragmented specimen the osteoid + osteoblasts can be over-called as osteosarcoma. The discriminators are the lack of cytologic atypia, the organised architecture, sharp circumscription, and absence of permeative growth, together with clinico-radiological correlation (a small nidus under 2 cm with reactive sclerosis). Never let the pathologist report a bone-forming lesion without the clinical and CT context.
- Versus osteoblastoma: the histology is the same - the distinction is size and behaviour, not the microscope.
Pain Pathophysiology
The nidus produces high levels of prostaglandin E2 (PGE2), which causes local vasodilation and oedema, sensitisation of nerve fibres, and the characteristic nocturnal pain pattern.
Why Night Pain?
- Circadian rhythm of prostaglandin production
- Decreased cortisol levels at night (anti-inflammatory)
- Venous stasis during recumbency increases pressure
Why NSAID Relief?
- COX inhibitors block prostaglandin synthesis
- Aspirin particularly effective (irreversible COX inhibition)
- Relief typically within 20-30 minutes
Location Distribution
- Percentage
- 30-35%
- Clinical Features
- Proximal femur/femoral neck common
- Percentage
- 20-25%
- Clinical Features
- Diaphysis most frequent
- Percentage
- 10-15%
- Clinical Features
- Posterior elements, painful scoliosis
- Percentage
- 10%
- Clinical Features
- Phalanges, atypical features
- Percentage
- 5-10%
- Clinical Features
- Similar to femur/tibia
- Percentage
- 10-20%
- Clinical Features
- Any bone possible
Anatomical Subtypes:
- Cortical (75%): Dense reactive sclerosis, classic presentation
- Cancellous (15%): Less sclerosis, more difficult to identify
- Subperiosteal (10%): Joint pain, synovitis, minimal sclerosis
The cortical type produces the classic radiographic appearance with extensive reactive sclerosis around a small nidus.
Classification Systems
Anatomical Classification
- Location
- Diaphyseal cortex
- Percentage
- 75%
- Clinical Features
- Classic presentation, dense sclerosis, night pain
- Location
- Metaphysis/epiphysis
- Percentage
- 15%
- Clinical Features
- Less sclerosis, harder to diagnose
- Location
- Under periosteum
- Percentage
- 10%
- Clinical Features
- Joint effusion, synovitis, minimal sclerosis
- Location
- Within joint capsule
- Percentage
- Subset of above
- Clinical Features
- Hip most common, mimics synovitis
The anatomical classification has important treatment implications. Cortical lesions are ideal for RFA while intra-articular and subperiosteal lesions may require arthroscopic or open excision to protect articular cartilage.
Clinical Assessment
History
Classic Presentation:
- Night pain that wakes the patient from sleep
- Pain relieved by aspirin or NSAIDs within 20-30 minutes
- Dull, aching pain gradually increasing over months
- Well-localised pain (can point with one finger)
Ask specifically about: time of pain (worse at night), NSAID response (dramatic relief), duration of symptoms (usually under 2 years), and any prior imaging studies.
Atypical Presentations:
- Intra-articular: Joint effusion, stiffness, mimics synovitis
- Spinal: Painful scoliosis in adolescents (concavity towards lesion)
- Near growth plate: Growth disturbance possible
- Hand/foot: Swelling, fusiform soft tissue enlargement
Physical Examination
Standard Findings:
- Point tenderness over the lesion
- Possible soft tissue swelling or warmth
- May have muscle wasting from chronic pain
- Usually normal range of motion (unless intra-articular)
Specific Location Findings:
- Examination Findings
- Hip pain, limited internal rotation, antalgic gait
- Examination Findings
- Localised tenderness, may feel cortical thickening
- Examination Findings
- Paravertebral muscle spasm, painful scoliosis
- Examination Findings
- Effusion, limited ROM, synovitis signs
Differential Diagnosis
- Key Differentiating Features
- Larger nidus over 2cm, less pain relief with NSAIDs, can be aggressive
- Investigation Findings
- CT: nidus over 2cm, may have expansion
- Key Differentiating Features
- History of infection, systemic symptoms possible, different pain pattern
- Investigation Findings
- MRI: rim enhancement, sequestrum possible
- Key Differentiating Features
- Activity-related pain, improves with rest, recent increase in activity
- Investigation Findings
- MRI: linear signal, cortical involvement
- Key Differentiating Features
- Age 5-25, systemic symptoms, permeative pattern, soft tissue mass
- Investigation Findings
- MRI: large lesion, aggressive features
- Key Differentiating Features
- Night pain, NSAID relief, nidus under 2cm on CT
- Investigation Findings
- CT: small nidus with reactive sclerosis
Investigations
Imaging Algorithm
Step 1: Plain Radiographs
- May be normal in early cases or cancellous locations
- Cortical thickening with central lucency (nidus)
- Variable sclerosis depending on location and duration
Step 2: CT Scan (Gold Standard)
- Defines nidus size, location, and calcification
- Essential for treatment planning (RFA trajectory)
- Thin-slice acquisition (1-2mm) through affected area
Step 3: MRI (Supplementary)
- Shows extensive marrow and soft tissue oedema
- May overestimate lesion extent (appears aggressive)
- Useful for intra-articular and spinal lesions
- Nidus may be obscured by reactive changes
Step 4: Bone Scan (If diagnosis uncertain)
- Very sensitive (nearly 100%)
- Double-density sign: focal uptake within larger area of uptake
- Useful for screening multiple sites or occult lesion
Imaging Characteristics
- Sensitivity
- 75%
- Key Findings
- Cortical thickening, central lucency
- Limitations
- May miss early/cancellous lesions
- Sensitivity
- Over 95%
- Key Findings
- Nidus with variable calcification, reactive sclerosis
- Limitations
- Radiation exposure
- Sensitivity
- 65-85%
- Key Findings
- Extensive oedema, nidus low signal
- Limitations
- May obscure nidus, appears aggressive
- Sensitivity
- Over 95%
- Key Findings
- Double-density sign, intense focal uptake
- Limitations
- Non-specific, poor anatomical detail
Always request CT if osteoid osteoma suspected. MRI alone may be misleading due to extensive oedema that can mimic infection or malignancy. The nidus may be obscured on MRI.
Laboratory Studies
Laboratory investigations are typically normal. FBC, ESR, CRP, and alkaline phosphatase are usually within normal limits. Laboratory tests mainly serve to exclude infection (elevated WCC, CRP, ESR in Brodie abscess) rather than to diagnose osteoid osteoma.
Management Algorithm
Treatment Decision Tree
Step 1: Confirm Diagnosis
- Clinical history (night pain, NSAID relief)
- CT scan showing nidus under 2cm
Step 2: Assess Location
- Standard location: Proceed to RFA
- Special location (spine, intra-articular, physis): Consider alternatives
Step 3: Patient Factors
- Preference for non-surgical: Trial of NSAIDs (lesion may resolve in 2-5 years)
- Requires definitive treatment: RFA or surgical excision
Treatment Options Summary
- Success Rate
- Over 90%
- Recovery
- 1-2 weeks
- Best For
- Most cortical lesions
- Success Rate
- 90-95%
- Recovery
- 4-8 weeks
- Best For
- RFA failure, physis, articular
- Success Rate
- Variable
- Recovery
- N/A
- Best For
- Patient preference, observation
The algorithm guides treatment selection based on lesion characteristics, location, and patient factors.
ABLATEABLATE - Treatment Principles
Hook:ABLATE the source of prostaglandins to cure the night pain
Surgical Technique
CT-Guided Radiofrequency Ablation
- Review CT for optimal trajectory
- Identify safe corridor avoiding neurovascular structures
- Position patient for access to lesion
- General anaesthesia preferred (patient comfort)
- Local anaesthesia possible in cooperative patients
- Periosteal local anaesthetic injection essential if LA
Step 1: Patient Positioning Position patient to allow CT scanner access and comfortable probe trajectory. Mark skin entry point based on planning CT.
Step 2: Sterile Preparation Standard sterile technique. Drape to allow CT imaging during procedure.
Step 3: Access Needle Placement Under intermittent CT guidance, advance coaxial needle to the cortex overlying the nidus. Confirm position on CT.
Step 4: Cortical Penetration Use hand drill or powered drill to penetrate cortex. Advance to nidus but not through it. Confirm position on CT.
Step 5: Biopsy (Optional) Core biopsy through needle for histological confirmation if diagnosis uncertain.
Step 6: RFA Probe Placement Insert RFA probe through coaxial system. Position tip at centre of nidus. Confirm on CT imaging.
Step 7: Ablation Heat to 90 degrees Celsius for 4-6 minutes. Monitor temperature and impedance.
Step 8: Probe Removal Allow probe to cool before removal. Remove coaxial system. Apply simple dressing.
This technique achieves complete nidus destruction while preserving surrounding bone.
Post-operative Protocol
- Weight bearing as tolerated immediately
- Simple analgesia for 24-48 hours
- Return to normal activity within 1 week
- Weight bearing dependent on bone removed
- May require protected weight bearing if significant cortex removed
- Activity restriction 4-6 weeks for bone healing
Complications
RFA Complications
- Incidence
- Under 5%
- Prevention/Management
- Maintain adequate distance from skin, use cooling
- Incidence
- Under 2%
- Prevention/Management
- Maintain over 1cm from nerves, use monitoring
- Incidence
- Under 1%
- Prevention/Management
- Avoid excessive cortical destruction, protect post-procedure
- Incidence
- 5-10%
- Prevention/Management
- Ensure complete nidus ablation, repeat RFA if needed
- Incidence
- Under 2%
- Prevention/Management
- Avoid RFA near articular surface, use chondroprotection
- Incidence
- Under 1%
- Prevention/Management
- Sterile technique, prophylactic antibiotics
Surgical Complications
- Incidence
- 5-10%
- Risk Factors
- Large cortical window, weight-bearing bone
- Incidence
- 5-15%
- Risk Factors
- Incomplete excision
- Incidence
- Under 2%
- Risk Factors
- Standard surgical risk
- Incidence
- Under 2%
- Risk Factors
- Deep location, poor visualisation
- Incidence
- Variable
- Risk Factors
- Intra-articular location
Managing Recurrence
Recurrence typically occurs within 2 years of treatment. Assessment includes return of typical night pain pattern and repeat CT to confirm residual or recurrent nidus.
Treatment Options:
- Repeat RFA (successful in most cases)
- Surgical excision if RFA fails twice
- En bloc excision for definitive cure
Persistent or recurrent pain after treatment requires repeat imaging. Do not assume treatment failure without confirming residual nidus on CT.
Postoperative Care
After RFA
- Discharge same day or next morning
- Weight bear as tolerated
- Simple analgesia (paracetamol, NSAIDs)
- Wound check at 1 week
- Return to normal activities
- No activity restrictions
- Clinical follow-up at 6 weeks
- CT only if symptoms persist/recur
- Discharge if asymptomatic at 6 months
After Surgical Excision
- Weight bearing status depends on extent of resection
- Minor cortical window: Weight bear as tolerated
- Significant resection: Protected weight bearing 4-6 weeks
- Wound management standard
- Physiotherapy if needed
- Monitor for fracture if significant bone removed
- Clinical review at 6 weeks, 3 months, 6 months
- Imaging only if symptoms recur
- Bone grafting site assessment if applicable
Return to Activity
- Return to Work
- 1-3 days
- Return to Sport
- 1-2 weeks
- Return to Work
- 1-2 weeks
- Return to Sport
- 4-6 weeks
- Return to Work
- 2-4 weeks
- Return to Sport
- 8-12 weeks
One of the major advantages of RFA is rapid recovery. Most patients are back to full activity within 1-2 weeks compared to 6-12 weeks for surgical excision.
Outcomes and Prognosis
Treatment Outcomes
- Primary success rate: 90-95%
- Recurrence rate: 5-10%
- Recurrence usually within 2 years
- Repeat RFA success: 85-90%
- Success rate: 88-100%
- Recurrence: 5-15%
- Higher morbidity but definitive
Prognostic Factors
- Cortical location (best RFA access)
- Complete nidus ablation/excision
- Small nidus size (under 1cm)
- Cancellous or intra-articular location
- Large nidus (approaching 2cm)
- Spinal location (technical challenges)
Long-term Prognosis
The prognosis is excellent. Osteoid osteoma is a benign lesion with no risk of malignant transformation. After successful treatment, long-term cure is expected in over 95% of cases. Untreated lesions will eventually spontaneously resolve in 3-6 years.
Functional Outcomes
- Full return to pre-morbid function
- No long-term restrictions
- Excellent patient satisfaction
- Generally full recovery
- May have residual bone defect on imaging
- Rarely causes functional limitation
Guidelines, Registries & Global Practice
Global Epidemiology
Osteoid osteoma accounts for roughly 10-12% of benign bone tumours and an estimated 2-3% of all primary bone tumours, with a consistent young-male predominance (peak 10-25 years, M:F approximately 2:1) reported across European, North American, and Asian series. There are no significant ethnic differences in incidence. The lower limb (femur and tibia) dominates, with the spine involved in roughly 10-15% of cases. According to PubMed, large multicentre and meta-analytic cohorts confirm this distribution: the European multicentre spinal series of Beyer et al. (Neuroradiology 2019, DOI) and the 749-patient meta-analysis of Sangiorgio et al. (Eur Spine J 2023, DOI) both report spinal lesions concentrated in the lumbar and thoracic posterior elements of adolescents and young adults.
Guideline & Society Positions
There is no single dedicated international clinical practice guideline for osteoid osteoma; practice is shaped by interventional-radiology and orthopaedic-oncology society consensus. The table below synthesises the dominant positions.
- First-line stance
- CT-guided thermal ablation (RFA) endorsed as standard of care for symptomatic OO
- Evidence basis
- Consensus / Level III cohort evidence
- First-line stance
- Percutaneous image-guided ablation first-line; surgery reserved for failure or inaccessible/critical sites
- Evidence basis
- Cohort and registry-type data
- First-line stance
- Ablation preferred; en bloc/curettage excision for diagnostic doubt, intra-articular cartilage risk, or physeal proximity
- Evidence basis
- Level III-IV expert consensus
- First-line stance
- No OO-specific guideline; suspected bone tumour referred via sarcoma/bone-tumour pathway to a specialist centre
- Evidence basis
- Referral-pathway guidance
Registry & Evidence Synthesis
Osteoid osteoma is benign and is not captured by arthroplasty joint registries; the closest equivalent to registry-level evidence is pooled multicentre data and meta-analysis. According to PubMed, the strongest synthesis is Sangiorgio et al. (Eur Spine J 2023, DOI): across 31 studies and 749 spinal cases, RFA and surgery achieved similar success (88.6% vs 85.6%) and recurrence (6.7% vs 5.6%), with fewer complications after RFA (4.4% vs 7.8%). The original comparative landmark, Rosenthal et al. (J Bone Joint Surg Am 1998, DOI), reported equivalent recurrence (12% RFA vs 9% surgery) with dramatically shorter hospital stay (0.2 vs 4.7 days).
Practice Variation
- Typical pathway
- CT-guided RFA as day-case via interventional radiology; surgery for critical-site or failed ablation
- Typical pathway
- Open surgical excision or supervised NSAID trial; referral to tumour unit
- Typical pathway
- Transfer to metropolitan tertiary centre for CT-guided ablation; diagnosis often delayed
Referral Pathway
Across high-income settings, CT-guided RFA is delivered through interventional radiology in metropolitan tertiary centres, with rural and remote patients commonly transferred for treatment. Suspected osteoid osteoma should be referred to an orthopaedic surgeon or musculoskeletal oncology unit, with interventional radiology involved for ablation and spinal-surgery or neurosurgery input for spinal lesions.
MCQ Practice Points
Q: What is the key size criterion distinguishing osteoid osteoma from osteoblastoma?
A: Osteoid osteoma nidus is under 2cm while osteoblastoma is over 2cm. Both lesions are histologically identical (osteoid and woven bone surrounded by vascular connective tissue), so size is the primary distinguishing feature. Osteoblastoma has higher recurrence rate and potential for malignant transformation.
Q: What is the gold standard imaging for osteoid osteoma diagnosis?
A: CT scan is the gold standard - it shows the nidus with surrounding reactive sclerosis clearly. MRI can obscure the nidus due to extensive bone marrow oedema. Bone scan shows "double density" sign but is non-specific. Always order CT if clinical suspicion is high, even with negative MRI.
Q: What is the first-line treatment for osteoid osteoma?
A: CT-guided radiofrequency ablation (RFA) is first-line treatment with over 90% success rate. It is minimally invasive, performed as day case, and allows immediate weight bearing. Recurrence rate is 5-10%. Surgical excision is reserved for RFA failure, intra-articular lesions near cartilage, or spinal lesions near neural structures.
Q: An adolescent presents with painful scoliosis that is worse at night. What diagnosis should be excluded?
A: Osteoid osteoma in the posterior spinal elements. Painful scoliosis in adolescence is osteoid osteoma until proven otherwise (idiopathic scoliosis is painless). The lesion is typically on the concave side of the curve. Early treatment allows curve resolution; curves present over 18 months may become structural.
Q: What is the classic clinical presentation of osteoid osteoma?
A: The classic triad is: (1) Night pain that wakes the patient from sleep, (2) NSAID relief - pain significantly improves with aspirin or ibuprofen (due to prostaglandin inhibition), (3) Young male aged 10-25 years. The mechanism is prostaglandin production by the nidus causing pain and local vasodilation.
Clinical Decision Scenarios
Practise clinical reasoning and management decisions out loud
“A 16-year-old male presents with 6 months of left thigh pain. Pain is worse at night and wakes him from sleep. He finds that ibuprofen helps significantly. Examination shows point tenderness over the mid-femur. X-rays show cortical thickening with a central lucency.”
“A 22-year-old female presents with 9 months of right hip pain and stiffness. She has been treated for hip synovitis with NSAIDs which provided significant relief. MRI shows extensive bone marrow oedema in the femoral neck with joint effusion. No clear lesion is identified.”
“A 14-year-old female presents with progressive painful scoliosis over 18 months. Pain is worse at night. Examination shows a 20-degree left thoracic curve with paravertebral muscle spasm. There is no neurological deficit.”
Key Diagnosis
- Nidus under 2cm differentiates from osteoblastoma
- Night pain relieved by NSAIDs (prostaglandin mechanism)
- CT is gold standard - MRI may obscure nidus
- Painful scoliosis = search for nidus on concave side
Treatment Algorithm
- RFA first-line treatment - over 90% success rate
- Spontaneous resolution possible in 3-5 years
- Surgical excision if RFA fails or near critical structures
RFA Surgical Steps
- CT guidance for probe trajectory planning
- Coaxial needle to cortex, drill through
- Position RFA probe at nidus centre
- Ablate at 90 degrees for 4-6 minutes
- Confirm position on post-procedure CT
Common Mistakes
- Relying on MRI alone - always get CT
- Confusing with osteoblastoma (size over 2cm)
- Performing RFA near cartilage without protection
- Missing spinal lesion in painful scoliosis
Exam Triggers
- Night pain in young patient = think osteoid osteoma
- NSAID-responsive bone pain = prostaglandin source
- Painful scoliosis = search for nidus on concave side
- CT showing nidus under 2cm = osteoid osteoma (not osteoblastoma)
Evidence and Guidelines
Landmark: RFA vs Operative Excision (Rosenthal)
- Consecutive series: 38 percutaneous RFA vs 87 operative excision (extraspinal lesions)
- Recurrence requiring re-intervention: 12% (4/33) after RFA vs 9% (6/68) after surgery for primary lesions - no significant difference
- Mean hospital stay 0.2 days for RFA vs 4.7 days for open surgery
- No complications in the RFA group; two patients required further operations after open excision
RFA vs Surgery for Spinal OO (Meta-analysis)
- 31 studies, 749 patients with spinal osteoid osteoma pooled
- Mean success: 88.6% RFA vs 85.6% surgical excision
- Recurrence: 6.7% (RFA) vs 5.6% (surgery)
- Complication rate: 4.4% (RFA) vs 7.8% (surgery)
Safety of RFA Near Neural Structures (Spinal Multicentre)
- 87 patients with spinal osteoid osteoma/osteoblastoma across six European centres
- Technical success 82/87 (94.3%) with NO major complications reported
- Clinical success (over 30% VAS reduction plus satisfaction) in 78/87 (89.7%)
- Mean pain score fell from 8.0 to 1.5 with three-dimensional access planning and thermal protection of adjacent neural structures
Diagnostic Accuracy of MRI for the Nidus
- 43 osteoid osteomas reviewed: potential missed-diagnosis rate of 35% on MRI alone
- Nidus identified in only 65% of axial-plane sequences; visible on a single optimal slice in many cases
- Reactive bone and soft-tissue oedema frequently misinterpreted as aggressive pathology
- Unexplained marrow oedema mandates CT/scintigraphy to exclude osteoid osteoma
Long-term Outcomes After CT-Guided RFA
- 81 RFA procedures in 77 patients (osteoid osteoma and osteoblastoma), including spinal and intra/peri-articular lesions
- Primary success 96.1% (74/77); secondary success 100% after retreatment of 3 patients
- Highly significant reduction in all limitation scores at mean 38.5-month follow-up (range 3-92 months)
- Only one major complication (cannula breakage); advanced techniques allowed treatment in critical locations
Conservative Management & Spinal OO in Childhood
- 30 paediatric spinal osteoid osteoma/osteoblastoma cases; 8 managed non-surgically
- 29/30 (97%) presented with pain and 23% with scoliosis at presentation
- Pain-free without medication in 38% (3/8) of non-surgically managed patients at mean 33-month follow-up
- Surgery achieved pain freedom in 73% when conservative therapy failed or tissue diagnosis was needed